BenevolentAI - treatment of neurological disorders

Proximagen Ltd’s UK business operations which includes the Proximagen UK team and facilities along with the discovery pipeline and related IP has been acquired by BenevolentAI. Saniona’s constructive collaboration with the Proximagen team continues under the BenevolentAI umbrella. Following the acquisition Proximagen will be renamed BenevolentAI. Saniona will therefore now refer to this collaboration as the BenevolentAI program.

BenevolentAI is the global leader in the development and application of artificial intelligence (AI) for scientific innovation.  It is the largest private AI company in Europe and one of the world’s top five private AI companies.  In the first instance BenevolentAI has applied its technology to accelerate the discovery of new medicines.  The technology enables a completely unique understanding of disease and can deliver significantly higher success rates in discovering new medicines and potential cures for disease.  BenevolentAI has made significant progress in accelerating drug development, initiated 19 validated drug research programmes, including a breakthrough in ALS in 2017, where positive results for its AI derived invention was announced. BenevolentAI has entered into significant license agreements with some of the world’s largest pharmaceutical companies and began its first Phase IIb clinical study in 2017.